Nicotex is an effective smoking cessation aid that reduces the withdrawal symptoms and craving for nicotine.
Nicotex is a product from Cipla Limited. Cipla is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.
Nicotine is a highly addictive chemical found in the tobacco plant. The addiction is physical, meaning habitual users come to crave the chemical, and also mental, meaning users consciously desire nicotine’s effects. Nicotine addiction is also behavioural. People become dependent on actions involved with using tobacco. They also become accustomed to using tobacco in certain situations, such as after meals or when under stress.
Patient w/ bipolar disorders (in the treatment of depression); recent history of MI or unstable heart disease; other risk factors for seizures (e.g. alcohol abuse, diabetes, history of head trauma). Renal or mild to moderate hepatic impairment. Elderly. Pregnancy and lactation. Patient Counselling This drug may cause dizziness and light headedness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP and LFT before and during treatment; monitor wkly if used w/ nicotine products. Monitor for worsening and emergence of suicidal thoughts and behaviours.
Current or history of seizure disorder, eating disorders (e.g. bulimia or anorexia nervosa); CNS tumour, epilepsy; history of bipolar disorder (when used as an aid in smoking cessation). Abrupt withdrawal of alcohol, benzodiazepines, barbiturates, antiepileptic drugs. Severe hepatic cirrhosis. Concomitant admin or w/in 14 days of MAOIs withdrawal.
Observe extreme caution w/ concurrent admin of drugs that lower seizure threshold (e.g. other antidepressants, antipsychotics, theophylline, systemic corticosteroids). Increased risk of side effects w/ levodopa or amantadine. Decreased exposure w/ CYP2B6 inducers (e.g. ritonavir, lopinavir, efavirenz). May increase exposure of CYP2D6 substrates (e.g. venlafaxine, fluoxetine, antipsychotics, β-blockers, type 1C antiarrhythmics.
Potentially Fatal: Concurrent use w/ MAOIs may cause acute toxicity symptoms and increased risk of fatality.
Symptoms: Hallucinations, nausea and vomiting, loss of consciousness, tachycardia, seizures. Management: Supportive treatment. Ensure adequate airway, ventilation and oxygenation. Administer activated charcoal for a dose >450 mg w/in 1 hr of ingestion. Perform gastric lavage to decrease absorption. May give benzodiazepine for seizures.
Oral: Store between 15-30°C.
Mechanism of Action
Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine, w/ minimal effect on serotonin reuptake. The mechanism by which it aids in smoking cessation is presumed to be mediated by its noradrenergic and/or dopaminergic actions.